Showing 1 - 4 results of 4 for search '"левожелудочково-артериальное сопряжение"', query time: 0.49s Refine Results
  1. 1
    Academic Journal

    Source: Rational Pharmacotherapy in Cardiology; Vol 14, No 2 (2018); 210-216 ; Рациональная Фармакотерапия в Кардиологии; Vol 14, No 2 (2018); 210-216 ; 2225-3653 ; 1819-6446 ; 10.20996/1819-6446-2018-14-2

    File Description: application/pdf

    Relation: https://www.rpcardio.com/jour/article/view/1650/1624; Tavazzi L., Senni M., Metra M., et al. Multicenter prospective observational study on acute and chronic heart failure: the one-year follow-up results of IN-HF outcome registry. Circ Heart Fail. 2013;6:47381. doi:10.1161/CIRCHEARTFAILURE.112.000161.; Maggioni A.P., Dahlstrom U., Filippatos G., et al. on behalf of the Heart Failure Association of the European Society of Cardiology (HFA). EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot). Eur J Heart Fail. 2013;15:80817. doi:10.1093/eurjhf/hft050.; Jhund P.S., Macintyre K., Simpson C.R., et al. Long-term trends in fist hospitalization for heart failure and subsequent survival between 1986 and 2003: a population study of 5.1 million people. Circulation. 2009;119:515-23. doi:10.1161/CIRCULATIONAHA.108.812172.; Ponikowski P., Voors A.A., Anker S.D., et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(27):2129-200. doi:10.1093/eurheartj/ehw128.; Yancy C.W., Jessup M., Bozkurt B., et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/ American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017;136(6):137-61. doi:10.1161/CIR.0000000000000509.; Braunwald E. The path to an angiotensin receptor antagonist neprilysin inhibitor in the treatment of heart failure. J Am CollCardiol. 2015;65:1029-41. doi:10.1016/j.jacc.2015.01.033.; Braunwald E. Academic-industrial collaboration in the development of the first angiotensin receptor blocker: neprilysin inhibitor in the treatment of heart failure. Eur Heart J. 2016;37:745-6. doi:10.1093/eurheartj/ehw055.; McMurray J., Packer M., Desai A., et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993-1004. doi:10.1056/NEJMoa1409077.; Мареев В.Ю., Фомин И.В., Агеев Ф.Т., Арутюнов Г.П. Хроническая сердечная недостаточность (ХСН) Клинические рекомендации (2016). Доступно на: http://scardio.ru/content/Guidelines/SSHF-Guidelines-rev.4.0.1.pdf. Проверено 16.04.2018.; Elzinga G., Westerhof N. Matching between ventricle and arterial load: an evolutionary process. Circ Res. 1991;68:1495-1500. doi:10.1161/01.RES.68.6.1495.; Sunagawa K., Maughan W.L., Sagawa K. Optimal arterial resistance for the maximal stroke studied in isolated canine left ventricle. Circ Res. 1985;56:586-95. doi:10.1161/01.RES.56.4.586.; Chantler P.D., Lakatta E.G., Najjar S.S. Arterial-ventricular coupling: Mechanistic insights into cardiovascular performance at rest and during exercise. J Appl Physiol. 2008;105:1342-51. doi:10.1152/japplphysiol.90600.2008.; Asanoi H., Sasayama S., Kameyama T. Ventriculoarterial coupling in normal and failing heart in humans. Circulation Research. 1989;65:483-93. doi:10.1161/01.RES.65.2.483.; Vlachopoulos C., Aznaouridis K., O’Rourke M.F., et al. Prediction of cardiovascular events and allcause mortality with central haemodynamics: a systematic review and meta-analysis. Eur Heart J. 2010;31:1865-871. doi:10.1093/eurheartj/ehq024.; McEniery C.M., Cockcroft J.R., Roman M.J., et al. Central blood pressure: current evidence and clinical importance. Eur Heart J. 2014,35:1719-25. doi:10.1093/eurheartj/eht565.; Williams B., Lacy P.S. Central aortic pressure and clinical outcomes. J Hypertens. 2009;27:1123-5. doi:10.1097/HJH.0b013e32832b6566.; Ky B., French B., May Khan A., et al. Ventricular-arterial coupling, remodeling, and prognosis in chronic heart failure. J Am Coll Cardiol. 2013;62:1165-72. doi:10.1016/j.jacc.2013.03.085.; Hoffman J.I., Buckberg G.D. The myocardial supply: demand ratio: a critical review. Am J Cardiol. 1978;41:327-32. doi:10.1016/0002-9149(78)90174-1.; Williams B., Cockcroft J.R., Kario K., et al. Effects of sacubitril/valsartan versus olmesartan on central hemodynamics in the elderly with systolic hypertension The PARAMETER Study. Hypertension. 2017;69:411-20. doi:10.1161/HYPERTENSIONAHA.116.08556.; Iborra-Egea O., Galvez-Monton C., Roura S., et al. Mechanisms of action of sacubitril/valsartan on cardiac remodeling: a systems biology approach. NPJ Syst Biol Appl. 2017;3:12. doi:10.1038/s41540-017-0013-4.; Hoskova L., Melenovsky V., Kautzner J., et al. Cardioprotective effect of LCZ696 versus valsartan on left ventricular remodeling in experimental model of chronic heart failure. Eur J Heart Failure. 2017;19 (Suppl. 1):168-9 (P640); Maurin V., Canu A., Bernard A., et al. Early reverse remodeling and improvement of echo parameters after introduction of sacubitril/valsartan in 80 stable and well treated HFrEF patients. Eur J Heart Failure. 2017;19(Suppl. 1):296 (P1189).; https://www.rpcardio.com/jour/article/view/1650

  2. 2
  3. 3
  4. 4